Go Unlimited with Magzter GOLD

Go Unlimited with Magzter GOLD

Get unlimited access to 10,000+ magazines, newspapers and Premium stories for just

$149.99
 
$74.99/Year
The Perfect Holiday Gift Gift Now

Taiwan's Success Story In Combating Covid-19

BioSpectrum Asia

|

May 2020

COVID-19 has unravelled the potency and the feebleness of most geographical region’s healthcare, technical, social and political structure. While countries are anticipating various dimensions to tackle coronavirus and combat the pandemic, Taiwan’s success in controlling COVID-19 has bolstered its global standing despite the close geographical proximity with China. The resilient island aggregated its forces to tackle the virus and circumstances rationally with well-established pandemic control strategies, bio medical assets, advanced IoT capabilities, impeccable healthcare system and a well organised political force. Taiwan apparently grappled the coronavirus incredibly well and is now keen to offer medical and technical assistance to other countries in this global crisis.

- Hithaishi C Bhaskar 

Taiwan's Success Story In Combating Covid-19

Taiwan, an island state in East Asia is located at less than 150 km sea route away from China, the epicentre of COVID-19 outbreak. Among the 23 million population of the island 850 000 reside-in and 404 000 work in China. Though the world’s corona death tool is steeping with elevated graph, Taiwan has recorded only 429 cases and 6 reported deaths as of April 30, 2020.

Taiwan has always been provident from its earlier lessons learnt during SARS outbreak in 2003. Thus, the country became hyper-vigilant once the first case of mysterious pneumonia reported in Wuhan, China. Taiwan developed its proficient and self-established health system to address any upcoming pandemic or epidemic. Taiwan’s advanced hub is combating COVID-19 through science, technology, and democratic proactive governance and most importantly independent of WHO tracking system. Taiwan believes in strategic pre planning prior to the outbreak and constantly reviews immigration policies as and when the situation evolves to monitor any emerging infectious diseases.

Taiwan’ trajectories and execution strategies in assessing COVID-19 and quick actions in preventing a large-scale epidemic may be instructive for other countries as the virus continue to threaten global health and economies.

Rapid response and effective strategies

Ever since the SARS epidemic in 2003, Taiwan has been on constant alert by establishing public health response mechanism which activates emergency public health management structures. Taiwan proficient teams quickly mobilize and institute specific approaches for case identification, containment, and resource allocation.

MORE STORIES FROM BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

"The next 5-years will see mRNA science evolve beyond infectious disease"

A new survey from Moderna Singapore reveals persistent vaccine hesitancy among older adults in Singapore, even as international travel and year-end gatherings increase the urgency of protection. The findings point to clear opportunities to strengthen public health, including empowering healthcare professionals as trusted messengers and promoting co-administration of vaccines.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

No Funding No Vax for TB?

The World Health Organization (WHO)'s latest updates on tuberculosis (TB) released on November 12 reveal significant progress in diagnosis, treatment, and political commitment, but also expose deep vulnerabilities—especially in the South-East Asia Region (SEARO)—related to funding gaps and the uncertain future of novel TB vaccines. SEARO remains the global epicentre of the TB epidemic, carrying more than 45 per cent of the world's TB incidence despite representing only a quarter of the global population.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Australia builds tailored heart pump to transform heart failure care

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to heart pump treatments and are left with only medication or palliative care.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Clinical Research Trends 2026: Hybrid DCTs Set for Surge as Innovation Outpaces Regulatory Hurdles

APAC's openness to innovation, combined with its large population and low trial density, creates strong potential for expanding decentralised clinical trials (DCTs), especially for patients with limited trial access. While regulatory diversity and operational challenges will continue to hinder fully decentralised models, the region is expected to adopt more digital technologies in clinical research. As a result, hybrid DCTs will keep gaining traction, and effective management of digitally collected data will remain a central focus for data science teams.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

CSL Seqirus to localise advanced influenza vaccine manufacturing in Saudi Arabia

Australia-based CSL Seqirus and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by accessing advanced cellbased seasonal and pandemic influenza vaccines and localising manufacturing in Saudi Arabia.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

How Sponsors Could Gain Advantage by Embracing Dose Optimisation in Asia by 2026

In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm toward evidence-based dose optimisation. Sponsors might consider adopting strategies similar to the FDA's Project Optimus, which emphasises selecting doses that balance efficacy and safety rather than relying solely on toxicity thresholds. Doing so could improve patient outcomes and position companies favourably as regulatory expectations evolve.

time to read

1 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm launches joint research with National Cancer Center in Japan

Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Monash spinout RAGE Biotech secures $29 M to advance next-generation RNA therapeutics

Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Submitting clinical data to the FDA and PDMA: An efficient and compliant approach

In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications governing submissions for marketing approval of new drugs and biologics. Fortunately, despite some differences, the regulations concerning clinical data have a surprising amount in common. It is possible that with a solid understanding of the requirements and an adherence to best practices, sponsors can develop some of the same material for submission to both countries.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Regenerative medicines and microbiome health are emerging as exciting frontiers, with Australian companies and researchers pushing into new therapeutic approaches

After more than a year at the helm of AusBiotech, CEO Rebekah Cassidy reflects on her early priorities and the organisation’s ambitions as Australia accelerates its position in the global life sciences economy. In an email interaction on the sidelines of AusBiotech 2025, she highlights the country's progress in mRNA, cell and gene therapy, and radiopharmaceuticals, outlines emerging areas of momentum, and discusses how new partnerships and MoUs are strengthening collaboration across the biotech ecosystem. Rebekah also outlines how AusBiotech is preparing Australia for a more competitive and connected global life sciences economy and the strategic priorities shaping AusBiotech’s next chapter. Edited excerpts:

time to read

7 mins

BioSpectrum Asia Dec 2025

Translate

Share

-
+

Change font size

Holiday offer front
Holiday offer back